About F-Star

We are a clinical-stage biotech creating a paradigm shift in cancer therapy with our advanced pipeline of immuno-oncology programs.

F-star is committed to delivering life-changing treatments for the estimated 80% of patients whose cancer fails to have a durable response to immunotherapies.

Our novel technology platform of tetravalent mAb2 bispecific antibodies have a natural human antibody format. This allows for a straightforward manufacturing process, and may provide a favorable safety profile and strong biological potency. Multiple clinical trials are underway.

Our product candidates are designed to simultaneously address multiple immune-evasion pathways that limit the effect of existing therapies. These are potentially first- and best-in-class drug candidates for patients with cancer who have few other options. F-star has over 500 granted and pending patents related to our platform technology and product pipeline.

Leadership

Our executive leadership team members have extensive experience in immuno-oncology and have worked with global pharmaceutical companies as well as biotechs, with a well-established track record of building biotech companies and developing biologics. Collectively, they have brought 20 drugs to market.

Eliot Forster, Ph.D.

President and Chief Executive Officer, Board member

Eliot Forster, Ph.D.

President and Chief Executive Officer, Board member

Dr. Eliot Forster has served as F-star’s President, Chief Executive Officer and a member of the Board of Directors since joining F-star in 2018. Dr. Forster has three decades of experience in the pharmaceutical and biotechnology industry, having co-founded and led several companies. He has raised more than $500M in equity financing. He is non-executive Chairman of Avacta plc and non-executive Director of Immatics NV (NASDAQ IMTX). He has previously served as Chief Executive Officer of Immunocore Ltd (NASDAQ IMCR), Creabilis Therapeutics and Solace PharmaceuticalsInc. and was also Head of Development and Operations for the EU and Asia at Pfizer.

He was founding Chairman of MedCity and is Chairman of Liverpool Health Partners.He is an honorary visiting Professor of Molecular and Clinical Cancer Medicine at theUniversity of Liverpool and an honorary international visiting Professor at the University of Pavia, Italy. He is also a Board member of the UK Office for Strategic Coordination of Health Research and the UK National Genomics Board. He holds a Ph.D. from University of Liverpool and an MBA from Henley Management College.

Darlene Deptula-Hicks

Chief Financial Officer

Darlene Deptula-Hicks

Chief Financial Officer

Ms. Deptula-Hicks has served as F-star’s Chief Financial Officer since May 2019. Since January 2018, Ms. Deptula-Hicks has operated Crimson Advisors, a strategic and financial consulting services company, and has served as acting Chief Financial Officer for Northern Biologics, Inc. from March 2018 to December 2020. She served as Senior Vice President and Chief Financial Officer of T2 Biosystems, Inc from May 2017 to January 2018, and from December 2014 to February 2017 Ms. Deptula-Hicks was Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. From 2012 until November 2014, she served as Vice President and Chief Financial Officer of Microline Surgical, Inc. Ms. Deptula-Hicks currently serves on the board of directors and audit committee chair of Abcuro, Inc. and Aerami Therapeutics and previously served on the board of directors and as audit committee chair of Giner Life Sciences, Xentic Biosciences a publicly traded biotechnology company, US Falcon, Inc. a privately held defense contractor, Technest Holdings, Inc. a publicly traded defense contracting company and, IMCOR Pharmaceuticals, a publicly traded biotechnology company. Ms. Deptula-Hicks received an M.B.A. from Rivier University and a B.S in Accounting from Southern New Hampshire University.

Neil Brewis, Ph.D.

Chief Scientific Officer

Neil Brewis, Ph.D.

Chief Scientific Officer

Dr. Brewis has served as F-star’s Chief Scientific Officer since 2015 and is a member of the Board of Directors. He began his career in academic research in cancer biology but after nine years was drawn to the applied nature of biotech. He subsequently took up the role of Head of Research at Domantis in 2002 and, following the company’s acquisition by GlaxoSmithKline in 2007, became Head of Biopharmaceuticals Research at GSK.

Dr. Brewis received his Ph.D. in Biochemistry from Dundee University and holds a B.Sc. with honors in Applied Biology and an Honorary Doctor of Science from Hertfordshire University.

Louis Kayitalire, M.D.

Chief Medical Officer

Louis Kayitalire, M.D.

Chief Medical Officer

Dr. Kayitalire brings over 20 years of experience in oncology and immuno-oncology to his position as Chief Medical Officer at F-star. He joined the company in 2019 from Bristol Myers Squibb where he was responsible for immuno-oncology clinical research development for a variety of tumor types and advancing clinical research efforts with a team of medical directors. Prior to that, Dr. Kayitalire held senior positions at major pharmaceutical companies on both sides of the Atlantic including Celgene from September 2013 to March 2016.

Dr. Kayitalire completed his medical training at Butare University, Rwanda, and later as Assistant Professor in Oncology at the Paris XI University of France. He is an active member of the American Society of Clinical Oncology (ASCO) , the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC).

James Sandy

Chief Development Officer

James Sandy

Chief Development Officer

Mr. Sandy joined F-star as Chief Development Officer (CDO) in March 2022, bringing over 35 years of experience in the pharmaceutical and biotechnology industries across all phases of drug development from clinical trials through regulatory approval. Most recently, Mr. Sandy served as Chief Development Officer at Ellipses Pharma, leading the clinical development of the Company’s portfolio of oncology assets. Previously, he was CDO at Immunocore, and at Creabilis Pharmaceuticals before that. Earlier in his career, he held senior positions at AstraZeneca and at Pfizer, leading development operations teams in Europe and Asia. He holds degrees in Biology and an MPhil in Statistics and Operational Research from Imperial College London.

Board of Directors

Nessan Bermingham Ph.D.

Chairman of the Board

Nessan Bermingham Ph.D.

Chairman of the Board

Dr. Bermingham has served as a member of F-star’s Board of Directors and as its chairman since May 2019. Dr. Bermingham previously served as F-star’s chairman and on the board of directors of F-star Alpha, F-star Beta and F-star Delta from April 2018 to May 2019. Dr. Bermingham also served as a member of the supervisory board of F-star GmbH until May 2019. Dr. Bermingham currently serves as an Operating Partner at Khosla Ventures. From Nov 2018 to Dec 2021 Dr Bermingham served as President, Chief Executive Officer and director of Triplet Therapeutics and is currently Exec Chair of the Board of Directors of Triplet Therapeutics. From Nov 2018 to present Dr Bermingham has served as Executive Chair of Korro Bio. From March 2018 to March 2020 Dr Bermingham served as Exec Chair of Xilio Therapeutics (fka Akrevia Therapeutics). From May 2014 to December 2017, Dr. Bermingham served as co-founder, President and Chief Executive Officer of Intellia Therapeutics, Inc. Prior to Intellia, from 2002 to 2007 and 2012 to 2014 Dr. Bermingham held various positions at Atlas Ventures including a member of the Atlas Venture Investment Team from 2002 to 2007. Dr. Bermingham was a Howard Hughes Assoc Fellow at Baylor College of Medicine, he received a Ph.D. in Molecular Biology from Imperial College London and a B.S. from Queen’s University Belfast.

David Arkowitz

Director

David Arkowitz

Director

Mr. Arkowitz has been a member of F-Star’s Board of Directors since January 2014. Since May 2018, Mr. Arkowitz has served as the Chief Financial Officer and Treasurer of Flexion Therapeutics, Inc., a biotechnology company. Prior to that, Mr. Arkowitz served from September 2013 to May 2018 as Chief Operating Officer and Chief Financial Officer of Visterra, Inc., which was acquired by Otsuka Pharmaceutical Co., Ltd., a biotechnology company. Prior to joining Visterra, he served from 20 11 to 2013 as Chief Financial Officer and General Manager at Mascoma Corporation, which was acquired by Lallemand, Inc., a bioconversion company. From 2007 to 2011, Mr. Arkowitz was Executive Vice President, Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a specialty pharmaceutical company. Prior to his tenure at AMAG, he served as Chief Financial Officer and Treasurer of Idenix Pharmaceuticals, Inc., which was acquired by Merck & Co. Inc., a biopharmaceutical company. Earlier in his career, he spent more than thirteen years at Merck & Co. Inc. including as Vice President and Controller of the U.S. Human Health division and as Controller of the Global Research and Development division. Mr. Arkowitz currently serves on the board of directors of Proteostasis Therapeutics, Inc., a publicly traded biotechnology company, and previously served on the board of directors of Aegerion Pharmaceuticals, Inc., also a publicly traded biotechnology company. Mr. Arkowitz has a BA in Mathematics from Brandeis University and an MBA in Finance from Columbia University Business School.

Edward Benz, Jr., M.D.

Director

Edward Benz, Jr., M.D.

Director

Dr. Benz joined the F-star Board of Directors in December 2019 and is a renowned leader in the field of hematology/oncology with a distinguished career spanning more than 40 years across industry and academia. Dr. Benz has been President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute, Boston, MA since October 2016. He has also served as the Richard and Susan Smith Distinguished Professor of Medicine, Professor of Pediatrics, Professor of Genetics and Faculty Dean Emeritus for Oncology at Harvard Medical School since November 2000. Former associate editor of the New England Journal of Medicine, and co-editor of prize-winning textbooks, Dr. Benz has authored over 300 peer-reviewed publications and holds several senior positions on various academic and biotech boards. He received his Doctor of Medicine from Harvard Medical School (magna cum laude) and holds an M.A. from Yale University (ad privatum) and a B.A. (cum laude) from Princeton University.

Todd Brady, M.D., Ph.D.

Director

Todd Brady, M.D., Ph.D.

Director

Dr. Brady has been a member of the F-star Board of Directors since 2020; and previously served on the board of Springbank prior to the merger. He currently serves as Chief Executive Officer, President, and Director of Aldeyra Therapeutics, Inc., a publicly traded biotechnology company focused on the development of novel drugs for the treatment of immune-mediated diseases. Dr. Brady was appointed President and Chief Executive Officer of Aldeyra Therapeutics in 2012, having been a member of the board of directors since 2005. Dr. Brady also served as Entrepreneur in Residence at Domain Associates, LLC, a healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady also currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded specialty pharmaceutical company, and has previously served on the board of directors of Oncobiologics, Inc. and numerous privately traded biotechnology companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. in Philosophy and Psychology from Dartmouth College.

Eliot Forster, Ph.D.

President and Chief Executive Officer, Board member

Eliot Forster, Ph.D.

President and Chief Executive Officer, Board member

Dr. Eliot Forster has served as F-star’s President, Chief Executive Officer and a member of the Board of Directors since joining F-star in 2018. Dr. Forster has three decades of experience in the pharmaceutical and biotechnology industry, having co-founded and led several companies. He has raised more than $500M in equity financing. He is non-executive Chairman of Avacta plc and non-executive Director of Immatics NV (NASDAQ IMTX). He has previously served as Chief Executive Officer of Immunocore Ltd (NASDAQ IMCR), Creabilis Therapeutics and Solace PharmaceuticalsInc. and was also Head of Development and Operations for the EU and Asia at Pfizer.

Pamela Klein M.D.

Director

Pamela Klein M.D.

Director

Dr. Klein has served as a member of F-Star’s Board of Directors since 2020; and previously served on the board of Springbank prior to the merger. Dr. Klein is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community, a position she has held since 2008. From 2009-2011, she served as Chief Medical Officer of Intellikine, which was acquired by Takeda. Previously, Dr. Klein spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Care Center, after which she joined Genentech in 2001. While at Genentech, she held roles of increasing responsibility including Vice President, Development. Dr. Klein currently serves as a member of various scientific advisory boards and also serves on the board of directors of argenx SE and I-Mab Biopharma, both publicly traded biotechnology companies. Dr. Klein is also a board member of Patrys Limited, a biotechnology company located in Australia. Dr. Klein holds a B.A. in biology from California State University and an M.D. from Stritch School of Medicine, Loyola University Chicago, and is trained in internal medicine and medical oncology.

Patrick Krol

Director

Patrick Krol

Director

Mr. Krol has served on F-star’s Board of Directors since May 2019 and served on the board of directors of F-star Alpha, F-star Beta and F-star Delta from their respective incorporation dates to May 2019. Mr. Krol also served on the board of directors of F-star GmbH from 2011 until May 2019.Mr. Krol is a seasoned biotech investor joining venture capital fund Aescap Venture at its start in 2005 and has served as its Managing Partner since 2009. In 2016, Mr. Krol founded Aescap Life Sciences, followed by Aescap Genetics in 2022.For both funds, that invest in public biotechnology companies, he acts as Portfolio Manager. From 1995 until 2004, Mr. Krol was the founder and Managing Director of Firm United Healthcare, a leading European life sciences consultancy. Mr. Krol served on the board of directors of 10 life sciences companies and was a statutory director at Shire International Licensing BV, a subsidiary of Shire PLC and later Takeda Pharmaceutical Company Ltd, from 2004 to 2022. Mr. Krol received an M.B.A. in Executive Management and Consultancy from Lemniscaat Management School. He started his studies in physical therapy at the Paramedic Academy in Utrecht, followed by a Master’s in business at the Business School Inholland.

Geoff Race

Director

Geoff Race

Director

Mr. Race joined the F-star Board of Directors in December 2019. Mr. Race brings more than 20 years of experience at both the Chief Financial and Chief Executive Officer level in the life sciences industry. Mr. Race is the President of Minerva Neurosciences Inc. (NASDAQ:NERV), a company he co-founded in 2013 through the merger of Cyrenaic Inc. and Sonkei Inc. Previously, in September 2011, Mr. Race was appointed Chief Executive Officer of Funxional Therapeutics Ltd, an early-stage research company focused on the treatment of inflammatory diseases. Funxional’s lead program was licensed to Boehringer Ingelheim in 2013. Prior to this role, Mr. Race was Chief Financial Officer of PanGenetics BV, which included clinical stage companies developing NGF and CD-40 antibodies, part of which was sold to Abbott Laboratories in 2009. Mr. Race received an MBA from Durham University Business School, UK, and is a Fellow of the Chartered Institute of Management Accountants.

Pharmaceutical Partnerships

F-star’s platform has been validated through partnerships for over a decade. We have collaboration and licensing agreements with many leading biopharma companies to research, develop, and commercialize therapies leveraging our modular antibody technology and mAb2 programs.  Our partners are targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS, among others.

Meet F-star Team Members

Sarah Batey

Vice President Project and Portfolio Management

Leon Beaudoin

Project Manager

Ioannis Diamantopoulos

Research Associate

Ryan Fiehler, Ph.D.

Associate Director, Discovery

Rafaella Giambalvo

Scientist

Jo Hume

Vice President of Finance

Trish Hurley

VP Regulatory Affairs & Clinical Operations

Daniel Jones

Clinical Pharmacology Lead

Swetang Khambhatwala

Senior Clinical Trial Leader

Matthew Lakins, Ph.D.

Senior Principal Scientist

Theo Levine

Apprentice

Martyn Rhoades, m.i.a.t.

Principal Research Associate

Chris Shepherd

Vice President, Clinical Development

Christel Veyssier

Director, Protein Sciences